MedTrace Logo

Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema

NCT02609165 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-09-06

No results posted yet for this study

Summary

This study aims at investigating the therapeutic potential of recombinant human Nerve Growth Factor ( rhNGF ) eye drops treatment in patients with Retinitis Pigmentosa (RP) associated with cystoid macular edema (CME) in a phase II, randomized, double-masked, controlled clinical trial.

Conditions

Interventions

DRUG

rhNGF 180 µg/ml eye drops solution

eye drops

DRUG

vehicle eye drops

placebo

Sponsors & Collaborators

  • Dompé Farmaceutici S.p.A

    collaborator INDUSTRY

  • Ospedale San Raffaele

    lead OTHER

Principal Investigators

  • Paolo Rama, MD · Ospedale San Raffaele. Milan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609165 on ClinicalTrials.gov